

CC subunit coding sequence
 XX Sequence 1184 BP; 356 A; 260 C; 255 G; 313 T; 0 U; 0 Other;
 SQ Query Match 100.0%; Score 1184; DB 4; Length 1184;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1184; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CTTAATCTATCCAGATGATGAGTACGCTCTTGGTGTCTCTATGAGACCCAGGGGATG 60
 1 CTTAATCTATCCAGATGATGAGTACGCTCTTGGTGTCTCTATGAGACCCAGGGGATG 60
 61 TTGGAAAGAACTGAGAGAAAGAGCAAAAGCGCGAGTGTGTGAGAGGAGCAGCGG 120
 61 TTGGAAAGAACTGAGAGAAAGAGCAAAAGCGCGAGTGTGTGAGAGGAGCAGCGG 120
 121 CTGTGGGGCCCTCCAGAGAAATGTACTGAAAAGTCTAGCAATGTCTGGGATTTGCTA 180
 121 CTGTGGGGCCCTCCAGAGAAATGTACTGAAAAGTCTAGCAATGTCTGGGATTTGCTA 180
 181 AACAAATACCTGGAAGAGAGAGAGTTTGGCATTCCTCCAGAGACATCCACATAGG 240
 181 AACAAATACCTGGAAGAGAGAGAGTTTGGCATTCCTCCAGAGACATCCACATAGG 240
 241 AAAGAGAGCCCTGGAGCAACATCTCTAAGATGTTTATATGAGACAGTGGCGGACCTT 300
 241 AAAGAGAGCCCTGGAGCAACATCTCTAAGATGTTTATATGAGACAGTGGCGGACCTT 300
 301 TCATCTTATAGCATGATGAAAAAGAAATATTTTACAGAAAAATCAGGAGCCATGACCTC 360
 301 TCATCTTATAGCATGATGAAAAAGAAATATTTTACAGAAAAATCAGGAGCCATGACCTC 360
 361 CTGGAGAAAGAAAGAAACATCTACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAG 420
 361 CTGGAGAAAGAAAGAAACATCTACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAG 420
 421 GGAAGTGGTATGATGTGTCTCTCATCATGATGATGATGATGATGATGATGATGATG 480
 421 GGAAGTGGTATGATGTGTCTCTCATCATGATGATGATGATGATGATGATGATGATG 480
 481 CGCTCTAATGATGAGAGCGGTGTGAGACGAGTCTCAATGCACTTGTGTAATGCTGTC 540
 481 CGCTCTAATGATGAGAGCGGTGTGAGACGAGTCTCAATGCACTTGTGTAATGCTGTC 540
 541 ATCAGAGAAACATTTAATGCTGCTCAGCTGGTGGCAGAGTCTGGAATCTTCTCAG 600
 541 ATCAGAGAAACATTTAATGCTGCTCAGCTGGTGGCAGAGTCTGGAATCTTCTCAG 600
 601 TACCCCTGCTCCAGAGTGTAGCTTAACTGACTTCTTCCGGGAAAAAGCTCCTCTAC 660
 601 TACCCCTGCTCCAGAGTGTAGCTTAACTGACTTCTTCCGGGAAAAAGCTCCTCTAC 660
 661 CACAGAGAGAGAAATTAATTAATGAGAGTGTCTTATATCTTAATAGTGGAAAA 720
 661 CACAGAGAGAGAAATTAATTAATGAGAGTGTCTTATATCTTAATAGTGGAAAA 720
 721 AATTTTGAAGATCCATGCTCCGTGTGATGATGATGATGATGATGATGATGATGATG 780
 721 AATTTTGAAGATCCATGCTCCGTGTGATGATGATGATGATGATGATGATGATGATG 780
 781 CACTTCTCTGCTATTTCTAACCAGAGAGAAACAGAGAGTGTATCTTCAACAAATC 840
 781 CACTTCTCTGCTATTTCTAACCAGAGAGAAACAGAGAGTGTATCTTCAACAAATC 840
 841 TACAGTTCAGAGTGTCTTCAATCACTCTTGTGGCAACTGTATGATGCTGGGGT 900
 841 TACAGTTCAGAGTGTCTTCAATCACTCTTGTGGCAACTGTATGATGCTGGGGT 900
 901 GTGGCAATTTGTCATGCTGTAATCTTACACAGTCTTCTCTCAATGATGAGAGATC 960
 901 GTGGCAATTTGTCATGCTGTAATCTTACACAGTCTTCTCTCAATGATGAGAGATC 960
 961 CAACGATCAATGATTAATGAGAAAAATGATTAATTTTGTAAAGCTCAAAATAC 1020

DB 961 CAACGATCAATGATTAATGAGAAAAATGATTAATTAATTTTGTAAAGCTCAAAATAC 1020
 QY 1021 TGTTCCTTCATCTTCCACCAAGAACCTTAAGTTGTAGTGTGAGTCTGTATAGT 1080
 DB 1021 TGTTCCTTCATCTTCCACCAAGAACCTTAAGTTGTAGTGTGAGTCTGTATAGT 1080
 QY 1081 TCCCTAATATATCTTATATGAGAGCAATATGCAAAAGCTGTCTATATGCAAAATG 1140
 DB 1081 TCCCTAATATATCTTATATGAGAGCAATATGCAAAAGCTGTCTATATGCAAAATG 1140
 QY 1141 ATGCTTATATATTCAGAGAAATTAATTAATCTGTTTGTGTA 1184
 DB 1141 ATGCTTATATATTCAGAGAAATTAATTAATCTGTTTGTGTA 1184

RESULT 2 SEQUENCE COMPARISON 'A'
 ID AA251632 standard; cDNA; 1300 BP.
 AA251632;
 21-JUN-2000 (first entry)

Human membrane channel protein-16 (MECHP-16) cDNA.
 KW Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;
 KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;
 KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;
 KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;
 KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nocturnal;
 KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiomy;
 KW Huntington's disease; Alzheimer's disease; Parkinson's disease; human;
 KW anti-HIV; anti-laemias; antileptoclosteric; hepatotropic; cytotoxic;
 KW hypotensive; vasotropic; antiaesthetic; immunomodulator; antidiabetic;
 KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant; ss.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH 378..1085
 FT CDS
 FT /tag= a
 FT /product= "MECHP-16"
 FT /note= "Shows homology to human beta subunit of Ca+
 FT activated K+ channel"
 FT 381..425
 FT /tag= b
 FT /bound_motey= "Primer or Probe"

WC0200012711-A2.
 XX
 XX 09-MAR-2000.
 PD
 XX 02-SEP-1999; 99MO-US020468.
 PF
 XX 02-SEP-1998; 98US-0155226P.
 PR 12-NOV-1998; 98US-00191283.
 PR 09-DEC-1998; 98US-0155225P.
 PR 26-JAN-1999; 99US-0155211P.
 PR 10-FEB-1999; 99US-0155263P.
 XX
 XX (INCY-) INCYTE PHARM INC.
 PA
 XX Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JT, Yue H;
 PI Lal P, Corley NC, Guegler KJ, Gorgone G, Baughm MR, Azimzai Y;
 PI WPI; 2000-256643/22.
 DR P-PSDB; AAY70466.
 XX Novel human membrane channel protein and polynucleotide useful for
 PT diagnosing and treating cell proliferative, inflammatory, secretory,
 PT osmoregulatory, muscular, cardiovascular and neurological disorders.

XX Claim 9: Page 128-129; 140pp; English.
 PS The present sequence is a cDNA identified in Incyte clone 2069907 derived
 SS from ISH1001 cDNA library. It encodes human membrane channel protein-16
 CC (MECHP-16), which is expressed in nervous tissues. Anti-MECHP antibodies
 CC can be used as therapeutic antagonists and reagents for diagnosis and
 CC monitoring diseases. MECHP cDNA can be used for diagnosis of MECHP-
 CC related diseases and gene mapping. MECHP can be used for treatment of
 CC cell proliferative disorders such as psoriasis and atherosclerosis,
 CC cancers like lymphoma and sarcoma, inflammatory disorders like AIDS and
 CC Addison's disease, transport/secretory disorders like cystic fibrosis and
 CC diabetes mellitus, osmoregulatory disorders like diarrhoea and renal
 CC failure, muscular disorders like myocardiitis and Duchenne's muscular
 CC dystrophy, cardiovascular disorders like hypertension and vasculitis,
 CC congenital lung anomalies like bronchitis and asthma and neurological
 CC disorders like Alzheimer's disease, Parkinson's disease and Huntington's
 CC disease
 XX
 SQ Sequence 1300 BP; 381 A; 288 C; 279 G; 352 T; 0 U; 0 Other;

Query Match 99.6%; Score 1179.2; DB 3; Length 1300;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 1181; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1 CTTAATCTATCCAGTATGAGTACGCTCTGGTCTGTCTATGAGACCCAGGGGATG 60
 108 CTTAATCTATCCAGTATGAGTACGCTCTGGTCTGTCTATGAGACCCAGGGGATG 167
 61 TTGGAAAGAACTGAGAGAAAGCAAAAGCGGCGAGTGTGTAGAGGGGAGAGCGCG 120
 168 TTGGAAAGAACTGAGAGAAAGCAAAAGCGGCGAGTGTGTAGAGGGGAGAGCGCG 227
 121 CTGTGGGGGCGCTCCGAGAGAAATGTACTGAAAAGCTGACGAATGCTGGGATTGGCTA 180
 228 CTGTGGGGGCGCTCCGAGAGAAATGTACTGAAAAGCTGACGAATGCTGGGATTGGCTA 287
 181 AACAACTACTGAGAAAGCAAGGTTTGTGCAATCTCTCCAGGACATCCACATAAG 240
 288 AACAACTACTGAGAAAGCAAGGTTTGTGCAATCTCTCCAGGACATCCACATAAG 347
 241 AAGAGAGACCTGAGCAACATCTCTAGATGTTTATGAGACAGTGGCGGACCTCT 300
 348 AAGAGAGACCTGAGCAACATCTCTAGATGTTTATGAGACAGTGGCGGACCTCT 407
 301 TCATCTTATGACATGATGAAAAAGAAATATTTACAGAAAATCAGGAGCCATGACCTC 360
 408 TCATCTTATGACATGATGAAAAAGAAATATTTACAGAAAATCAGGAGCCATGACCTC 467
 361 CTGGAGAAAAGAAAAAGCTCAGACACTGAAAGCGAGAGAGCCAGCTATTTCTCTG 420
 468 CTGGAGAAAAGAAAAAGCTCAGACACTGAAAGCGAGAGAGCCAGCTATTTCTCTG 527
 421 GGAAGTGGATGATGGTGTGCTCCATCATGATGATGATGATGATGATGATGATGATG 480
 528 GGAAGTGGATGATGGTGTGCTCCATCATGATGATGATGATGATGATGATGATGATG 587
 481 CGCTCATACATGAGAGCGTGTGAGACGAGAGAGTCAATGACCTTGTGTAATGCTGC 540
 588 CGCTCATACATGAGAGCGTGTGAGACGAGAGAGTCAATGACCTTGTGTAATGCTGC 647
 541 ATCAGAGAAACATTTAATGCTCTTCACTGAGTGGCGAGATGCTGAGAACTTTCTGAG 600
 648 ATCAGAGAAACATTTAATGCTCTTCACTGAGTGGCGAGATGCTGAGAACTTTCTGAG 707
 601 TACCCCTGCTCCAGGTGTAGCTTAACCTGACTTCTTCGGGGGAAAAGCTCTCTCTAC 660
 708 TACCCCTGCTCCAGGTGTAGCTTAACCTGACTTCTTCGGGGGAAAAGCTCTCTCTAC 767
 661 CACACGAGAGAGCAATTAATTAATCAATGAGAGTGTCTCTATATCTTAATGAGGAAA 720
 768 CACACGAGAGAGCAATTAATTAATCAATGAGAGTGTCTCTATATCTTAATGAGGAAA 827

QY 721 AATTTGAGAGATCCATGTCCTCCCTGTAATGTTGTCTAGTGAAGAACTCAGAGATATCAA 780
 DB 828 AATTTGAGAGATCCATGTCCTCCCTGTAATGTTGTCTAGTGAAGAACTCAGAGATATCAA 887
 QY 781 CACTTCTCTGCTATTTCTGAGACCAAGAGAGAGTGTATCTTACCAAACTC 840
 DB 888 CACTTCTCTGCTATTTCTGAGACCAAGAGAGAGTGTATCTTACCAAACTC 947
 QY 841 TACAGTTCCAAAGTCTGTTTCCATCTCTTCTGAGCACTGTATGATGCTGGGGGT 900
 DB 948 TACAGTTCCAAAGTCTGTTTCCATCTCTTCTGAGCACTGTATGATGCTGGGGGT 1007
 QY 901 GTGGCAATTTGTGCTGATGAGAACTTACACAGACCTCTCCCTCATGTGAGAGATC 960
 DB 1008 GTGGCAATTTGTGCTGATGAGAACTTACACAGACCTCTCCCTCATGTGAGAGATC 1067
 QY 961 CACGAGTCAATGATTAATGCAAAAATGGAATAAATATTTTGTAAAGCTCAATAC 1020
 DB 1068 CACGAGTCAATGATTAATGCAAAAATGGAATAAATATTTTGTAAAGCTCAATAC 1127
 QY 1021 TGTCTTCTCATCTTCCACCAAGAACCTTATGATGAGTGTGATGAGT 1080
 DB 1128 TGTCTTCTCATCTTCCACCAAGAACCTTATGATGAGTGTGATGAGT 1187
 QY 1081 TCCCTAATATATTTCTTATATGATGAGCAATATGCAAAAAGCTGTCTATATGCAAACTG 1140
 DB 1188 TCCCTAATATATTTCTTATATGATGAGCAATATGCAAAAAGCTGTCTATATGCAAACTG 1247
 QY 1141 ATGCTTATATTTATGAGAAATTAATTAATTAATTAATTTTGTGTGA 1184
 DB 1248 ATGCTTATATTTATGAGAAATTAATTAATTAATTAATTTTGTGTGA 1291

RESULT 3

AAA26355 ID AAA26355 standard; cDNA; 2098 BP.

AAA26355; AC

29-JUN-2000 (first entry) DT

Human secreted protein gene 10 SEQ ID NO:20. DB

Human; secreted protein; diagnosis; cytosolic; immunosuppressive; KW

antihIV; antiinflammatory; neurotropic; neuroprotective; antiallergic; KW

osteopathic; antiatheritic; antibacterial; antidiabetic; asthma; KW

antiporiatic; cardiac; gene therapy; cancer; neurological disorder; KW

immune disease; inflammation; blood disorder; tumour; ss. KW

Homo sapiens. OS

MO200006698-A1. PN

10-FEB-2000. PD

29-JUL-1999; 99NO-US017130. PF

30-JUL-1998; 98US-0094657P. PR

05-AUG-1998; 98US-0095486P. PR

06-AUG-1998; 98US-0095454P. PR

12-AUG-1998; 98US-0096319P. PR

(HUMA-) HUMAN GENOME SCI INC. PA

Komatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y; PI

Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA; PI

Sopfer DR, Endress GA, Ebner R, Olsen HS, Mucenski M; PI

WPI, 2000-195282/17. DR

P-PSDB; AA91460. DR

New isolated human genes and the secreted polypeptides they encode, PT